RecruitingPhase 1NCT03830320

Positron Emission Tomography (PET) Imaging of Thrombosis

Preliminary Evaluation of [64Cu]FBP8 in Healthy Individuals and Subjects With Known or at Risk of Developing Thrombosis

Sponsor

Massachusetts General Hospital

Enrollment

165 participants

Start Date

Apr 1, 2016

Study Type

INTERVENTIONAL

Conditions

Cancer Atrial Fibrillation Thrombosis COVID-19

Summary

The purpose of the study is to evaluate a new radiotracer called 64Cu-FBP8 for PET-MR imaging of thrombosis. The tracer has the potential of detecting thrombosis anywhere in the body, for instance in the left atrial appendage of patients with atrial fibrillation, and thereby may provide a non-invasive alternative to the current standard-of-care methods.

Eligibility

Min Age: 18 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new PET scan imaging technique to detect blood clots inside the body — including in the heart, veins, or lungs — more accurately than current methods, in patients with conditions like atrial fibrillation (irregular heartbeat), COVID-19, or cancer. **You may be eligible if...** - You have a history of atrial fibrillation (an irregular heartbeat) and are scheduled for or recently had a heart ultrasound to check for clots, OR - You have tested positive for COVID-19 within the last month and do not require a breathing machine, OR - You have been diagnosed with cancer, OR - You have another condition where a blood clot is suspected or confirmed by ultrasound or CT scan **You may NOT be eligible if...** - You require a mechanical ventilator to breathe (for COVID-19 patients) - You do not meet the criteria for any of the eligible patient groups Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.